1. Show article details.

    BRIEF-Aerpio And Quantum Leap Announce Selection Of Razuprotafib For Testing in COVID-19 Trial

    Reuters – 6:06 PM ET 05/27/2020

    Aerpio Pharmaceuticals Inc (ARPO): * AERPIO PHARMACEUTICALS, INC. AND QUANTUM LEAP HEALTHCARE COLLABORATIVE ANNOUNCE THE SELECTION OF RAZUPROTAFIB FOR EVALUATION IN THE I-SPY COVID TRIAL FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN COVID-19 PATIENTS.

  2. Show article details.

    Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients

    PR Newswire – 4:30 PM ET 05/27/2020

    SAN FRANCISCO and CINCINNATI, May 27, 2020  Aerpio Pharmaceuticals (ARPO), Inc. and Quantum Leap Healthcare Collaborative™ announced today an agreement has been reached to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19.

  3. Show article details.

    Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients

    GlobeNewswire – 4:30 PM ET 05/27/2020

    Aerpio Pharmaceuticals, Inc. (ARPO) and Quantum Leap Healthcare Collaborative™ announced today an agreement has been reached to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19.

  4. Show article details.

    BRIEF-Aerpio Pharmaceuticals Says Announced Restructuring Of Licensing Deal With Unit Of Gossamer Bio

    Reuters – 6:12 PM ET 05/12/2020

    Aerpio Pharmaceuticals Inc (ARPO): * AERPIO ANNOUNCES AMENDED LICENSING DEAL WITH GOSSAMER BIO ON ITS INFLAMMATORY BOWEL DISEASE PRODUCT CANDIDATE GB004. * Aerpio Pharmaceuticals Inc (ARPO) - ANNOUNCED A RESTRUCTURING OF LICENSING DEAL WITH UNIT OF GOSSAMER BIO.

  5. Show article details.

    Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)

    GlobeNewswire – 4:30 PM ET 05/12/2020

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced a restructuring of their licensing deal with a wholly owned subsidiary of Gossamer Bio Inc. (GOSS), GB004, Inc., for  its  HIF-1 alpha stabilizer, GB004.

  6. Show article details.

    BRIEF-Aerpio Pharmaceuticals Reports Q1 Financial Results

    Reuters – 8:59 AM ET 05/07/2020

    Aerpio Pharmaceuticals Inc (ARPO): * AERPIO REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q1 LOSS PER SHARE $0.10. * AS OF MARCH 31, 2020, CASH AND CASH EQUIVALENTS TOTALED $34.6 MILLION Source text for Eikon: Further company coverage:

  7. Show article details.

    Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update

    GlobeNewswire – 8:00 AM ET 05/07/2020

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the first quarter ended March 31, 2020, and provided a business update. “We continue to be excited about our glaucoma program,” said Joseph Gardner, President and Founder.

  8. Show article details.

    BRIEF-Aerpio Pharmaceuticals Reports Q4 Loss Per Share Of $0.11

    Reuters – 8:43 AM ET 03/16/2020

    Aerpio Pharmaceuticals Inc (ARPO): * AERPIO REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q4 LOSS PER SHARE $0.11. * AERPIO PHARMACEUTICALS (ARPO)- TO ADVANCE AKB-9778 TOPICAL FORMULATION INTO PHASE 2 TRIAL IN OPEN ANGLE GLAUCOMA WITH TOP LINE RESULTS EXPECTED IN Q1 2021 Source text for Eikon: Further company coverage:

  9. Show article details.

    Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    GlobeNewswire – 8:00 AM ET 03/16/2020

    Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021 Conference Call and Webcast Today, March 16, 2020 at 8:30 a.m. EST CINCINNATI, March 16, 2020 -- Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic ...

  10. Show article details.

    Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020

    GlobeNewswire – 5:00 PM ET 03/12/2020

    Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, will release its financial results for the fourth quarter and full year ended December 31, 2019, before the market open on Monday, March 16, 2020, and host a webcast and conference call at 8:30am ET.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • May
    07

    ARPO announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.